ATE347910T1 - Zusammensetzungen zur behandlung von ischamischem gewebe - Google Patents

Zusammensetzungen zur behandlung von ischamischem gewebe

Info

Publication number
ATE347910T1
ATE347910T1 AT96936690T AT96936690T ATE347910T1 AT E347910 T1 ATE347910 T1 AT E347910T1 AT 96936690 T AT96936690 T AT 96936690T AT 96936690 T AT96936690 T AT 96936690T AT E347910 T1 ATE347910 T1 AT E347910T1
Authority
AT
Austria
Prior art keywords
tissue
ischemia
ischemic
treating
isamic
Prior art date
Application number
AT96936690T
Other languages
English (en)
Inventor
Jeffrey M Isner
Original Assignee
St Elizabeth S Medical Ct Of B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24178424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347910(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by St Elizabeth S Medical Ct Of B filed Critical St Elizabeth S Medical Ct Of B
Application granted granted Critical
Publication of ATE347910T1 publication Critical patent/ATE347910T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Laser Surgery Devices (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT96936690T 1995-10-20 1996-10-18 Zusammensetzungen zur behandlung von ischamischem gewebe ATE347910T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/545,998 US6121246A (en) 1995-10-20 1995-10-20 Method for treating ischemic tissue

Publications (1)

Publication Number Publication Date
ATE347910T1 true ATE347910T1 (de) 2007-01-15

Family

ID=24178424

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96936690T ATE347910T1 (de) 1995-10-20 1996-10-18 Zusammensetzungen zur behandlung von ischamischem gewebe
AT05270064T ATE419014T1 (de) 1995-10-20 1996-10-18 Verbindungen zur behandlung der ischaemischen gewebe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05270064T ATE419014T1 (de) 1995-10-20 1996-10-18 Verbindungen zur behandlung der ischaemischen gewebe

Country Status (8)

Country Link
US (1) US6121246A (de)
EP (2) EP1625858B1 (de)
JP (3) JPH11514366A (de)
AT (2) ATE347910T1 (de)
AU (1) AU725290B2 (de)
CA (1) CA2235372C (de)
DE (2) DE69637800D1 (de)
WO (1) WO1997014307A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
WO1995003843A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
EP0751992B1 (de) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
KR100765687B1 (ko) * 1995-08-29 2007-10-11 안제스에무지 가부시키가이샤 Ｈｇｆ 유전자를 함유하는 약제
IL125756A (en) 1996-02-15 2003-05-29 Biosense Inc Catheter for use in surgery
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
CA2278621A1 (en) 1997-01-29 1998-07-30 Cornell Research Foundation, Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
WO1998039035A1 (en) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
WO1999017798A1 (en) * 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
JP2001525173A (ja) * 1997-12-04 2001-12-11 ジェンザイム・コーポレーション 遺伝子発現を誘導するための組成物および方法
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
EP1132365B1 (de) 1998-11-13 2007-11-07 Daikin Industries, Ltd. Azeotropes gemisch aus 1,1,1,3,3-pentafluoropropan und 1,1,1-trifluoro-3-chloro-2-propen, eine methode zur trennung und reinigung derselben und ein verfahren zur herstellung von1,1,1,3,3-pentafluoropropan und 1,1,1-trifluoro-3-chloro-propen
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
EP1067190A1 (de) * 1999-07-09 2001-01-10 Introgene B.V. Gentherapie zur Erhöhung und/oder Induktion der Angiogenese
EP1132098B1 (de) * 1999-09-21 2010-05-26 AnGes MG, Inc. Gentherapie für zerebrale gefässerkrankungen
ATE395087T1 (de) 1999-10-08 2008-05-15 Anges Mg Inc Hgf zur gentherapie der karidomyopathie
ATE409494T1 (de) * 1999-10-29 2008-10-15 Anges Mg Inc Gentherapie für diabetische ischämie
US6748258B1 (en) * 1999-11-05 2004-06-08 Scimed Life Systems, Inc. Method and devices for heart treatment
US6329348B1 (en) 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
US20040072785A1 (en) * 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
AU2001266338B8 (en) * 2000-06-27 2006-12-14 Anges Mg, Inc. Pharmaceutical compositions for angiogenic therapy
US7273751B2 (en) * 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
CN1526014A (zh) * 2000-10-06 2004-09-01 ��ʽ���������о��� 用于将外源基因导入骨骼肌的副粘病毒载体
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
JP2004527462A (ja) * 2000-11-01 2004-09-09 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 血管新生活性のｉｎｖｉｖｏ刺激
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
ES2305138T3 (es) * 2000-11-27 2008-11-01 Dnavec Research Inc. Vector de paramixovirus que codifica factor 2 de crecimiento de fibroblastos (fgf2) y uso del mismo.
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20020168739A1 (en) * 2001-03-09 2002-11-14 Wu Kenneth K. Vectors, compositions and methods for treating a vascular disorder
US20020131959A1 (en) * 2001-03-14 2002-09-19 Ivo Buschmann Means and methods for the modulation of arteriogenesis
AU2002303243A1 (en) * 2001-04-05 2002-10-21 The Johns Hopkins University Imaging nucleic acid delivery
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
DE10122855A1 (de) * 2001-05-11 2002-11-14 Max Planck Gesellschaft Mittel zur Verbesserung der Gewebepenetration
WO2003000009A2 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
WO2003018752A2 (en) * 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US20040031067A1 (en) * 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
RU2232022C1 (ru) * 2002-12-02 2004-07-10 Государственное образовательное учреждение высшего профессионального образования башкирский государственный медицинский университет Способ профилактики и лечения ишемической болезни сердца
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US6817068B2 (en) * 2003-01-02 2004-11-16 The Burton Corporation Adjustable length strap assembly
WO2004098534A2 (en) * 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
CA2557737C (en) * 2003-03-12 2014-08-05 Advisys, Inc. Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications
WO2004087063A2 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica Nv Use of erythropoietin in stroke recovery
NZ543717A (en) * 2003-06-05 2008-06-30 Centelion Administration of a plasmid encoding a fibroblast growth factor (FGF), wherein VEGF-A factor expression is not induced in the myocardial or skeletal muscle to treat myocardial or skeletal angiogenic disorders or defects associated with hypercholesterolemia or diabetes
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2081956B1 (de) 2006-11-13 2013-03-20 Charité - Universitätsmedizin Berlin Zellkulturverfahren und behandlungsverfahren mit einer vepo-protein-variante
ES2520044T3 (es) * 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
CA2709398C (en) * 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
KR101290322B1 (ko) * 2008-04-09 2013-07-26 주식회사 바이로메드 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제
JP5856059B2 (ja) 2009-08-28 2016-02-09 ザ クリーブランド クリニック ファウンデーション 虚血組織を治療するためのｓｄｆ−１送達
EP2496946B1 (de) * 2009-11-03 2015-07-15 Roche Diagniostics GmbH NT-pro-ANP und sFlt-1 zur Differenzierung zwischen Kreislauf- und Ischämiereignissen
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
JP6571537B2 (ja) 2013-03-13 2019-09-04 ザ ユニバーシティー オブ クイーンズランド 療法および予防のための細胞を単離する方法
JP6240337B2 (ja) 2013-10-22 2017-11-29 バイロメッド カンパニー リミテッド 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
AU2019305221B2 (en) 2018-07-19 2024-11-07 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737750B1 (de) * 1989-03-21 2003-05-14 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE69233725T2 (de) * 1991-06-28 2009-02-12 The Regents Of The University Of Michigan, Ann Arbor Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6086866A (en) * 1993-04-29 2000-07-11 Kouri; Roger Khalil Use of platelet-derived growth factor to improve collateral circulation
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy

Also Published As

Publication number Publication date
EP0883343A4 (de) 2002-04-10
JP2008024718A (ja) 2008-02-07
US6121246A (en) 2000-09-19
JP2011219502A (ja) 2011-11-04
WO1997014307A1 (en) 1997-04-24
AU725290B2 (en) 2000-10-12
AU7454896A (en) 1997-05-07
EP0883343A1 (de) 1998-12-16
CA2235372C (en) 2009-01-27
DE69637800D1 (de) 2009-02-12
JPH11514366A (ja) 1999-12-07
DE69636764D1 (de) 2007-01-25
EP1625858A1 (de) 2006-02-15
EP1625858B1 (de) 2008-12-31
ATE419014T1 (de) 2009-01-15
EP0883343B1 (de) 2006-12-13
CA2235372A1 (en) 1997-04-24
DE69636764T2 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
DE69636764D1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
ATE339450T1 (de) Verfahren zur behandlung von entzündungen
ATE145564T1 (de) Anordnung zur bestrahlung von laserstrahlen
EA200300845A1 (ru) Модифицированные антитела и способы применения
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
EA199801044A1 (ru) Модуляторы регенерации тканей
CA2265508A1 (en) Bone morphogenetic protein-16 (bmp-16) compositions
BR9915573A (pt) Processo de preparação de uma composição protéica e uma fórmula infantil contendo a mesma
DE69434431D1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
DE69032200D1 (de) Verfahren zur Behandlung von Schnittblumen
FI900808A0 (fi) Humant mannos bindande protein.
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
WO1999029718A3 (en) Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions thereof
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
EA200001124A1 (ru) Способ генной терапии
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
EP1734827A4 (de) Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties